Artwork

Innhold levert av ACOFP. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av ACOFP eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.
Player FM - Podcast-app
Gå frakoblet med Player FM -appen!

Innovations in Type 1 Diabetes

13:09
 
Del
 

Manage episode 423304019 series 3574590
Innhold levert av ACOFP. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av ACOFP eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.

This episode of ACOFP's DO.fm Clinical podcast features Jay Shubrook, DO, FAAFP, FACOFP discussing Type 1 diabetes (T1D). We delve into the importance of screening and early intervention, the increasing prevalence in adults, the importance of patient-centered care and new and evolving technologies that are aiding in treatment and management of T1D.

Dr. Shubrook does disclose relationships with Abbott, Bayer and Novo Nordisk as a non-CE consultant and AstraZeneca, Eli Lilly and Novo Nordisk as an advisory board member. This podcast has been reviewed by non-conflicted physicians to ensure any potential conflicts are mitigated.

Mentioned in this episode:

De-stress Pain Management

  continue reading

4 episoder

Artwork
iconDel
 
Manage episode 423304019 series 3574590
Innhold levert av ACOFP. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av ACOFP eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.

This episode of ACOFP's DO.fm Clinical podcast features Jay Shubrook, DO, FAAFP, FACOFP discussing Type 1 diabetes (T1D). We delve into the importance of screening and early intervention, the increasing prevalence in adults, the importance of patient-centered care and new and evolving technologies that are aiding in treatment and management of T1D.

Dr. Shubrook does disclose relationships with Abbott, Bayer and Novo Nordisk as a non-CE consultant and AstraZeneca, Eli Lilly and Novo Nordisk as an advisory board member. This podcast has been reviewed by non-conflicted physicians to ensure any potential conflicts are mitigated.

Mentioned in this episode:

De-stress Pain Management

  continue reading

4 episoder

Minden epizód

×
 
Loading …

Velkommen til Player FM!

Player FM scanner netter for høykvalitets podcaster som du kan nyte nå. Det er den beste podcastappen og fungerer på Android, iPhone og internett. Registrer deg for å synkronisere abonnement på flere enheter.

 

Hurtigreferanseguide

Copyright 2024 | Sitemap | Personvern | Vilkår for bruk | | opphavsrett